CKD-581, a novel histone deacetylase inhibitor, synergistically enhances Bortezomib cytotoxicity in multiple myeloma cells

被引：1
|
作者：
Lee, Chansu [1 ]
Ahn, Kwang-Sung [2 ]
Jung, Woo June [1 ]
Koh, Youngil [2 ]
Kim, Hyo Jung [3 ]
Lee, Hyun Jung [4 ]
Yoon, Hwi-Joong [5 ]
Yoon, Sung-Soo [6 ]
机构：
[1] Seoul Natl Univ, Coll Med, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[3] Hallym Univ, Coll Med, Med Ctr, Seoul, South Korea
[4] Dongguk Univ, Ilsan Med Ctr, Seoul, South Korea
[5] Kyung Hee Univ, Sch Med, Med Ctr, Seoul, South Korea
[6] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Seoul, South Korea
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1695
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1695
引用
收藏
页数：1
相关论文
共 50 条
  • [11] CKD5, a Novel Pan-Histone Deacetylase Inhibitor, Synergistically Enhances the Efficacy of Sorafenib for Hepatocellular Carcinoma
    Chang, Young
    Kang, Seong Hee
    Cho, Eun Ju
    Lee, Hyo-Young
    Yoon, Jun Sik
    Lee, Jeong-Hoon
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan, Sr.
    HEPATOLOGY, 2018, 68 : 1258A - 1258A
  • [12] Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway
    Hsu, Fu-Shun
    Wu, June-Tai
    Lin, Jing-Yi
    Yang, Shao-Ping
    Kuo, Kuan-Lin
    Lin, Wei-Chou
    Shi, Chung-Sheng
    Chow, Po-Ming
    Liao, Shih-Ming
    Pan, Chun-I
    Hong, Jo-Yu
    Chang, Hong-Chiang
    Huang, Kuo-How
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (05):
  • [13] Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors
    Pei, XY
    Dai, Y
    Grant, S
    CLINICAL CANCER RESEARCH, 2004, 10 (11) : 3839 - 3852
  • [14] Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells
    Qiu, Xu-Hua
    Shao, Jing-Jing
    Mei, Jian-Gang
    Li, Han-Qing
    Cao, Hong-Qin
    ACTA HAEMATOLOGICA, 2016, 135 (02) : 103 - 109
  • [15] A novel notch pathway inhibitor blocks osteoclast activity and synergistically induces apoptosis with the proteasome inhibitor bortezomib in multiple myeloma cells
    Jundt, Franziska
    Schwarzer, Rolf
    Kaiser, Martin
    Acikgoez, Oezlem
    Heider, Ulrike
    Mathas, Stephan
    Preissner, Robert
    Sezer, Orhan
    Dorken, Bemd
    BLOOD, 2007, 110 (11) : 455A - 455A
  • [16] Marcks Peptide Inhibitor Displays Synergistic Cytotoxicity with Bortezomib in Drug Resistant Multiple Myeloma Cells but Enhances Autophagic Effect
    Zhang, Lun
    Abdi, Jahangir
    Wang, Minjing
    Rastgoo, Nasrin
    Chang, Hong
    BLOOD, 2016, 128 (22)
  • [17] Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells
    Ju, Donghong
    Xie, Youming
    MOLECULAR MEDICINE REPORTS, 2014, 10 (05) : 2609 - 2612
  • [18] A novel HDAC inhibitor, CKD-581 demonstrates a potent in vivo efficacy in various human tumor xenograft models
    Kim, Mi Jeong
    Lee, Chang Sik
    Han, Byeong Hoon
    Yang, Hyun-mo
    Lee, Kyung Joo
    Kim, Se-Mi
    Oh, Hyun Taek
    Lim, Ln-Taek
    Shin, Hyoju
    Bae, Daeil
    Kim, Dal-Hyun
    Lee, Sungsook
    Hong, Chung Ii
    CANCER RESEARCH, 2010, 70
  • [19] Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Vogl, Dan T.
    Raje, Noopur
    Jagannath, Sundar
    Richardson, Paul
    Hari, Parameswaran
    Orlowski, Robert
    Supko, Jeffrey G.
    Tamang, David
    Yang, Min
    Jones, Simon S.
    Wheeler, Catherine
    Markelewicz, Robert J.
    Lonial, Sagar
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3307 - 3315
  • [20] Chidamide, a novel histone deacetylase inhibitor inhibits multiple myeloma cells proliferation through succinate dehydrogenase subunit A
    Sun, Yifeng
    Li, Jing
    Xu, Zhao
    Xu, Jiadai
    Shi, Miaojie
    Liu, Peng
    AMERICAN JOURNAL OF CANCER RESEARCH, 2019, 9 (03): : 574 - 584
12345